Recent Developments in HLA B27 Anterior Uveitis.
Acute Disease
Animals
Bacteria
/ immunology
Cytokines
/ antagonists & inhibitors
Gastrointestinal Microbiome
Genetic Predisposition to Disease
HLA-B27 Antigen
/ genetics
Haplotypes
Humans
Immunosuppressive Agents
/ therapeutic use
Intestines
/ microbiology
Tumor Necrosis Factor Inhibitors
/ therapeutic use
Uvea
/ drug effects
Uveitis, Anterior
/ drug therapy
HLA B27
acute anterior uveitis
microbiome
pathogenesis
review
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
09
2020
accepted:
23
11
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
24
6
2021
Statut:
epublish
Résumé
There has been steady progress in understanding the pathogenesis, clinical features, and effective treatment of acute anterior uveitis (AU) over the past 5 years. Large gene wide association studies have confirmed that AU is a polygenic disease, with overlaps with the seronegative arthropathies and inflammatory bowel diseases, associations that have been repeatedly confirmed in clinical studies. The role of the microbiome in AU has received increased research attention, with recent evidence indicating that human leukocyte antigen B27 (HLA B27) may influence the composition of the gut microbiome in experimental animals. Extensive clinical investigations have confirmed the typical features of acute AU (AAU) and its response to topical, regional and systemic immunosuppressive treatment. Increased understanding of the role of cytokines has resulted in studies confirming the value of anti-cytokine therapy [anti-tumor necrosis factor (anti-TNF) and interleukin 6 (IL-6) therapy] in severe and recurrent cases of AAU, particularly in subjects with an associated spondyloarthopathy (SpA) and in juvenile idiopathic arthritis (JIA)-associated AAU.
Identifiants
pubmed: 33469457
doi: 10.3389/fimmu.2020.608134
pmc: PMC7813675
doi:
Substances chimiques
Cytokines
0
HLA-B27 Antigen
0
Immunosuppressive Agents
0
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
608134Informations de copyright
Copyright © 2021 Wakefield, Clarke and McCluskey.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Ophthalmol. 2010 Mar;149(3):423-32.e1-2
pubmed: 20042178
Arch Ophthalmol. 1990 Feb;108(2):219-21
pubmed: 2302105
Curr Mol Med. 2018 Mar 9;17(7):460-467
pubmed: 29424310
Clin Microbiol Rev. 2004 Apr;17(2):348-69
pubmed: 15084505
Invest Ophthalmol Vis Sci. 1992 Mar;33(3):532-9
pubmed: 1544781
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):3
pubmed: 32492107
Curr Opin Ophthalmol. 2004 Aug;15(4):293-8
pubmed: 15232467
Drugs Aging. 1999 Dec;15(6):439-50
pubmed: 10641955
Am J Med. 1988 Dec 23;85(6A):51-3
pubmed: 2462350
Ocul Immunol Inflamm. 2020 Apr 2;28(3):453-462
pubmed: 31161935
J Autoimmun. 1998 Jun;11(3):255-64
pubmed: 9693974
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Scand J Rheumatol. 2009;38(5):353-6
pubmed: 19296404
Clin Exp Immunol. 1991 Dec;86(3):399-404
pubmed: 1747948
J Clin Rheumatol. 2008 Feb;14(1):50-2
pubmed: 18431102
Clin Immunol. 2011 May;139(2):177-84
pubmed: 21334264
J Biol Chem. 1998 Aug 21;273(34):22128-35
pubmed: 9705358
Int Ophthalmol. 2017 Feb;37(1):139-145
pubmed: 27154720
Arthritis Rheum. 2009 May;60(5):1311-6
pubmed: 19404948
Ann Rheum Dis. 2006 Dec;65(12):1631-4
pubmed: 16901960
Mol Cell Proteomics. 2017 Apr;16(4):642-662
pubmed: 28188227
Semin Ophthalmol. 2017;32(6):689-701
pubmed: 27404944
Br J Ophthalmol. 2018 Feb;102(2):215-219
pubmed: 28607176
Ocul Immunol Inflamm. 2016;24(2):167-72
pubmed: 25325834
Lancet. 2007 Apr 21;369(9570):1379-1390
pubmed: 17448825
J Korean Med Sci. 2009 Aug;24(4):722-8
pubmed: 19654959
Ann Rheum Dis. 2017 Sep;76(9):1515-1521
pubmed: 28254789
Ocul Immunol Inflamm. 2016 Aug;24(4):440-4
pubmed: 27002532
Arthritis Rheumatol. 2017 Apr;69(4):774-784
pubmed: 28002888
J Immunol. 2004 Oct 15;173(8):4859-66
pubmed: 15470026
Ocul Immunol Inflamm. 2018;26(4):584-594
pubmed: 28112975
Ophthalmology. 2009 Nov;116(11):2188-98.e1
pubmed: 19748676
Cochrane Database Syst Rev. 2016 Feb 12;2:CD010469
pubmed: 26866343
FEMS Immunol Med Microbiol. 2009 Mar;55(2):178-86
pubmed: 19159429
Arthritis Rheum. 2005 Nov;52(11):3586-95
pubmed: 16255049
Prog Retin Eye Res. 2010 Nov;29(6):610-21
pubmed: 20813201
Clin Rev Allergy Immunol. 2012 Feb;42(1):102-11
pubmed: 22095454
Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1985-1992
pubmed: 30069748
Ophthalmology. 2002 Dec;109(12):2342-6
pubmed: 12466181
Growth Factors. 2004 Jun;22(2):75-7
pubmed: 15253382
Ocul Immunol Inflamm. 2021 Feb 17;29(2):237-243
pubmed: 31940227
Prog Retin Eye Res. 2004 Nov;23(6):617-37
pubmed: 15388077
Rheumatol Ther. 2018 Jun;5(1):5-20
pubmed: 29516402
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1711-7
pubmed: 17389503
Arthritis Rheumatol. 2015 Mar;67(3):702-13
pubmed: 25418920
Am J Ophthalmol. 1988 Jun 15;105(6):603-6
pubmed: 3259836
Ocul Immunol Inflamm. 2011 Apr;19(2):108-14
pubmed: 21428748
Curr Eye Res. 1992;11 Suppl:1-9
pubmed: 1424734
Prog Retin Eye Res. 2018 May;64:84-95
pubmed: 29357307
Ocul Immunol Inflamm. 2004 Sep;12(3):193-201
pubmed: 15385196
Front Immunol. 2018 Jul 30;9:1773
pubmed: 30105034
Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S12-7
pubmed: 18570749
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):665-72
pubmed: 24477536
BMJ. 2018 Jan 8;360:j5145
pubmed: 29311119
JAMA. 2017 May 16;317(19):1993-2005
pubmed: 28477440
Ophthalmology. 2010 Mar;117(3):576-84
pubmed: 20031223
Br J Ophthalmol. 1996 Apr;80(4):332-6
pubmed: 8703885
Rom J Morphol Embryol. 2019;60(2):601-604
pubmed: 31658334
Br J Ophthalmol. 1996 Sep;80(9):844-8
pubmed: 8962842
Clin Rheumatol. 2009 Jan;28(1):11-6
pubmed: 18688674
Ophthalmology. 2019 Feb;126(2):283-295
pubmed: 30269924
Lancet. 1995 Jun 17;345(8964):1542-4
pubmed: 7791441
Nat Rev Rheumatol. 2018 Dec;14(12):704-713
pubmed: 30301938
Arthritis Rheum. 2005 Aug;52(8):2447-51
pubmed: 16052578
Immunity. 2015 Aug 18;43(2):343-53
pubmed: 26287682
Ocul Immunol Inflamm. 2021 Apr 3;29(3):558-565
pubmed: 31763950
PLoS One. 2014 Aug 20;9(8):e105684
pubmed: 25140823
Ocul Immunol Inflamm. 1999 Jun;7(2):85-92
pubmed: 10420203
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4606-13
pubmed: 27603722
Acta Ophthalmol. 2019 Feb;97(1):e122-e128
pubmed: 30242977
Orphanet J Rare Dis. 2012 Aug 29;7:57
pubmed: 22932001
Mol Cell Proteomics. 2016 Jun;15(6):1867-76
pubmed: 26929215
Arthritis Rheumatol. 2015 Jan;67(1):140-51
pubmed: 25200001
Int Ophthalmol Clin. 2005 Spring;45(2):1-13
pubmed: 15791154
J Interferon Cytokine Res. 2011 Oct;31(10):733-44
pubmed: 21787221
Br J Ophthalmol. 2003 Jul;87(7):925
pubmed: 12812909
Joint Bone Spine. 2016 Dec;83(6):665-668
pubmed: 26992953
Am J Ophthalmol. 2020 Mar;211:76-86
pubmed: 31726034
Ocul Immunol Inflamm. 2016 Aug;24(4):470-5
pubmed: 27232197
Nature. 1980 Feb 21;283(5749):782-4
pubmed: 7354870
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9330-4
pubmed: 8415702
Am J Ophthalmol. 2009 Oct;148(4):500-509.e2
pubmed: 19570522
Ann Rheum Dis. 2009 May;68(5):696-701
pubmed: 18662932
Am J Ophthalmol. 1987 Feb 15;103(2):137-45
pubmed: 3492916
Front Immunol. 2017 Apr 10;8:417
pubmed: 28443096
West J Med. 1992 Aug;157(2):133-8
pubmed: 1279899
Clin Exp Immunol. 1986 Jan;63(1):49-57
pubmed: 3485486
J Ophthalmic Inflamm Infect. 2018 Apr 17;8(1):6
pubmed: 29666980
J Immunol. 2001 Oct 15;167(8):4738-46
pubmed: 11591805